2 completed, 1 recruiting. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Monument Therapeutics Limited: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis MT1988 Low Dose, MT1988 High Dose, Placebo - Clinical High Risk for Psychosis (CHR) | Phase 1 / Phase 2 | Recruiting | Monument Therapeutics Limited | 150 | 2026-03-03 | 2026-06-08 |
| Safety and PK of Multiple Doses of MT1988 MT1988, Placebo - Healthy Volunteer | Phase 1 | Completed | Monument Therapeutics Limited | 42 | 2024-11-25 | 2025-04-17 |
| Safety & PK of Single Doses of MT1980 MT1980, Placebo - Neuroinflammatory Response | Phase 1 | Completed | Monument Therapeutics Limited | 24 | 2022-06-01 | 2022-11-02 |
Neuroinflammatory Diseases (1)
Netherlands (1) · United Kingdom (1) · United States (1)
Martha E Shenton, PhD (1) · Scott Woods, M.D. (1)
U01MH137298 (1), U24MH137171 (1)